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The microenvironment in tumors is
known to induce vascular endothelial
cells to form new blood vessels for sup-
porting expansion of the tumor mass
(Hanahan and Folkman, 1996). New
blood vessels arise from preexisting cap-
illaries or postcapillary venules in
tumors, and/or by recruiting endothelial
precursor cells from the bone-marrow
stem cell pool (Rafii and Lyden, 2003).
As an initial step, endothelial cells
migrate toward angiogenic stimuli
derived from the tumor cells. In spite of
the extensive studies on the involvement
of angiogenic factors, such as vascular
endothelial cell growth factor (VEGF),
basic fibroblast growth factor (bFGF),
and cell adhesion molecules such as
integrins and cadherins (Jain, 2003),
tumor-endothelial cell communication
signals for directional movement are not
well defined. In this issue of Cancer Cell,
Wang and colleagues uncover a novel
mechanism for tumor-induced angiogen-
esis by demonstrating that tumor cells
secrete the Slit protein to attract vascular
endothelial cells expressing the cognate
receptor Robo (Figure 1). Slit-Robo sig-
naling thus becomes a “must see” to
researchers in the field of
tumor angiogenesis.
Slit was originally identi-
fied in Drosophila as an extra-
cellular cue to guide axon
pathfinding, to promote axon
branching, and to control
neuronal migration (Nusslein-
Volhard et al., 1984; Rothberg
et al., 1988). Mammalian Slit
consists of three members,
Slit1, Slit2, and Slit3. All are
expressed in the nervous sys-
tem but Slit2 and 3 can also
be found on other cell types.
The Slit gene encodes a
secreted protein possessing
multiple putative protein bind-
ing motifs, including four
leucine-rich repeats (LRRs),
nine (seven in Drosophila)
EGF-like repeats, a laminin G
domain, and a C-terminal
cysteine-rich knot (Rothberg
et al., 1990).
Robo, the receptor for Slit, was also
initially isolated from Drosophila in a
genetic screen for mutations affecting
axon pathfinding (Kidd et al., 1998). Four
(three in Drosophila) Robo genes have
thus far been identified in organisms
ranging from Drosophila and C. elegans
to mice and humans. Like Slit, all Robo
members are primarily expressed in the
nervous system, but three of them are
found in non-neuronal tissues. Robo is a
member of the neural cell adhesion mol-
ecule (NCAM) family and is character-
ized as a single-pass transmembrane
receptor with an extracellular region con-
taining five immunoglobulin (Ig) domains
and three fibronectin type III repeats and
an intracellular tail composed of four
conserved motifs (CC0, CC1, CC2, and
CC3) (Kidd et al., 1998).
Multiple investigations in the neuro-
biology and immunology fields have
established a primary role for Slit-Robo
as guides for neuronal migration and
leukocyte trafficking by acting as repel-
lents (Wong et al., 2002). Slit-Robo may
also signal for directing the movement of
epithelial sheaths (Schimmelpfeng et al.,
2001) and for controlling muscle precur-
sor cell migration during Drosophila
myogenesis (Kramer et al., 2001).
Interestingly, the guiding signal of Slit
seems switched from a repellent in the
early phase of muscle precursor cell
migration to an attractant during the late
phase of myofiber attachment to the epi-
dermis. The study by Wang et al. in this
issue (Wang et al., 2003) has now signif-
icantly extended the spectrum of Slit-
Robo signaling to the area of tumor
angiogenesis. In tumors, Slit-Robo sig-
nals work as attractant rather than repel-
lent.
In tumor development and metasta-
sis, infiltration of endothelial cells into
tumor mass, induction of vessel
formation, and invasion of tumor cells into
blood vessels involve intimate crosstalk
between tumor and endothelial cells
leading to coordinate cell migration.
Researchers working on guidance cues
of neuronal migration have hypothesized
that extracellular molecules, such as
netrins, semaphorins, ephrins, and the
Slits, may also function in mediating
tumor angiogenesis and tumor meta-
stasis because (1) DCC (Deleted in
Colorectal Cancer), Neuropilin, and Ephs,
the receptors for netrins,
semaphorins, and ephrins,
respectively, are expressed
on some tumors and
endothelial cells; and (2) Slit-
Robo, which seems to be a
conserved guiding signal for
cells of distinct types, has
recently been detected in
human prostate tumors (Latil
et al., 2003). Wang and
collaborators investigated the
potential involvement of Slit-
Robo signaling in tumor
angiogenesis. They demon-
strated expression of Slit2 in
a broad spectrum of tumor
cell lines, such as A375
(human melanoma), SCaBER
(bladder squamous carcino-
ma), SK-N-SH (neuroblas-
toma), NCI-H446 (small cell
lung cancer), T24 (transitional
cell carcinoma of urinary
bladder), LoVo (colon adeno-
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Slit and Roundabout (Robo) are well-characterized for neuron and leukocyte guidance. Their governing roles have now
been expanded to control tumor-endothelial cell communication and mediate tumor-induced angiogenesis.
Figure 1. Tumor induces angiogenesis through Slit-Robo signaling
Tumor cells secrete the Slit2 protein which forms a gradient field for the
attraction of endothelial cells through interaction with Robo1 on
endothelial cell surfaces. Endothelial cells migrate toward tumor mass
and form new blood vessels. Tumor and endothelial cells are repre-
sented by blue and red, respectively.
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carcinoma), ZR-75-30 (breast cancer),
CNE (nasopharyngeal carcinoma),
SMMC-7721 (hepatocellular carcinoma),
Acc (adenoid cystic carcinoma of salivary
gland), and A673 (rhabdomyosarcoma),
as well as a variety of primary tumors,
including human melanoma, rectal
mucinous adenocarcinoma, invasive
breast carcinoma, gastric squamous car-
cinoma, and hepatocellular carcinoma.
Intriguingly, the expression levels of Slit2
in primary tumors appear to correlate with
both microvessel density and extent of
cancerous alterations, supporting its criti-
cal role for tumorigenesis. There appears
to be a gradient of Slit2 protein expression
in tumors with higher concentrations near
the center of the tumor and decreased
levels in the periphery, thus creating a sig-
naling gradient field for the attraction of
endothelial cells. The team showed the
presence of Robo1 on HUVECs (human
umbilical vein endothelial cells) and, more
importantly, on a melanoma grown in
immunodeficient mice. It remains unclear
whether expression of Robo1 or other
Robo family members is universally pre-
sented on the vasculature of other solid
tumors that secrete Slit2. Attraction of
endothelial cells by Slit2 is mediated
through direct interaction with Robo1. Like
its role in guidance of cellular movement
of neurons and leukocytes, Slit2 controls
directional rather than random migration
of endothelial cells. Tumor-derived Slit2
seems to specifically attract endothelial
cells and does not affect immune cells
since there is no difference in the num-
bers of inflammatory cells inside and out-
side of the A375-derived melanoma.
However, studies in an immunocompetent
host will have to confirm such specificity.
Participation of Slit2 in regulating
angiogenesis has first been shown by its
ability in inducing vascular network for-
mation of HUVECs in vitro. The angio-
genic activity of Slit2 is dose dependent
and can be inhibited by its antagonist,
RoboN, a soluble form of Robo, or by
blocking antibodies. A critical role for Slit-
Robo signaling in mediating tumor-
induced angiogenesis has been further
demonstrated in the xenograft melanoma
model. Both the density of microvascular
vessels in the tumor tissue and the size of
the tumor mass were dependent on Slit2
signaling. Tumor size was enlarged if the
tumor cells overexpress Slit2 while
decreased if soluble RoboN was intro-
duced. It remains to be investigated
whether the Slit2-Robo1 interaction is
unique or whether redundancy exists.
Blocking Slit-Robo binding does not
affect normal vasculogenesis since the
vascular phenotype appears normal in
slit1, 2−/− mice (Plump et al., 2002).
However, a conclusion cannot be made
unless all members of Slit or Robo fami-
lies have been deleted. It would be inter-
esting to see whether Slit-Robo are
involved in tumor metastasis or function
in other biological processes such as
wound healing or rheumatoid arthritis.
One would also be curious whether Robo
is expressed on endothelial precursor
cells which have been known to migrate
and integrate into tumor vessels.
Two important yet less investigated
issues are the mechanisms that regulate
gene expression of Slit-Robo and their
downstream signaling networks in
endothelial cells. In vitro, proinflammato-
ry cytokines, such as TNF-α and IL-1β
can upregulate expression of Slit2 in
A375 melanoma cells. Since expression
of Slit2 is observed in tumors, it appears
obvious to explore whether expression of
Slit is governed by the same genetic
alternations that drive malignant conver-
sion or whether hypoxia or angiogenic
factors induce its expression. Similarly,
because Robo is concomitantly
expressed in the tumor vasculature, one
should ask whether Slit induces Robo
expression.The PI3-K pathway has been
implicated in mediating Slit2-Robo1 sig-
naling. Activation of this pathway might
explain why Slit-Robo function as attrac-
tants in directing endothelial cell move-
ment versus repellents for guidance of
migration of neurons and leukocytes.
Whether other signaling molecules
known to deliver Slit-Robo signaling,
such as srGAPs, Cdc42, Abelson (Abl),
Enabled (Ena), PTPases, and cyclic
nucleotides (for review, see Wong et al.,
2002), are also involved in Slit-Robo sig-
naling in tumor angiogenesis and what
mechanism determine signal for attrac-
tion or repulsion need to be addressed.
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